FreeBioList

Catalysts / ANVS

Annovis Bio (ANVS) catalysts

Upcoming FDA decisions and readouts we track for Annovis Bio, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 2 Rows last checked — 12 Sep 2026

FreeBioList tracks 2 upcoming catalysts for Annovis Bio (ANVS, listed on Nasdaq). Both concern Buntanetap (Alzheimer’s disease — 6-month symptomatic data; Alzheimer’s disease — disease-modifying data).

First on the list: the Phase 3 readout for Buntanetap (Alzheimer’s disease — 6-month symptomatic data), guided by the company to Q1 2027. By stage, the upcoming rows are 2 Phase 3 readouts.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker
ANVS
Next catalyst
Q1 2027
Type
Phase 3 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Annovis Bio ANVS · Nasdaq Buntanetap Alzheimer’s disease — 6-month symptomatic data Q1 2027
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes
Annovis Bio ANVS · Nasdaq Buntanetap Alzheimer’s disease — disease-modifying data Q1 2028
company guidance		 Phase 3 readout Verified 8-K exhibit 99.1 ↗ Yes

Companies working on related conditions

Also due in Q1 2027